NCT03976856View on ClinicalTrials.gov

Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

PHASE1UnknownINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 23, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2022

Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
DRUG

GB226

Geptanolimab, 210mg，q2w，ivgtt.

DRUG

Fruquintinib

Fruquintinib, 3mg or 4mg or 5mg, qd.po. 3 weeks-on,1 week-off

Trial Locations (1)

200000

RECRUITING

Shanghai chest hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

Hutchison Medipharma Limited

INDUSTRY

lead

Genor Biopharma Co., Ltd.

INDUSTRY